Personalized Immunonutrition and Gene Editing for Surgery-Induced Cachexia Prevention

A next-generation approach to preventing and treating surgery-induced cachexia through wearable devices, machine learning algorithms, novel compositions of matter, and gene editing technology, providing personalized and real-time interventions.

The original patent disclosed compositions and methods for treating or preventing surgery-induced cachexia and/or expression of myeloid-derived suppressor cells and pro-inflammatory cytokines. However, these methods rely on standardized supplements and do not account for individual variations in biomarkers, genetic predispositions, or real-time physiological responses. The new inventive concept addresses these limitations by introducing personalized, adaptive, and precision-based approaches to cachexia prevention and treatment.

The new inventive concept comprises a system for personalized nutrition, utilizing wearable devices to monitor biomarkers and administer customized immunonutrition supplements in real-time. Additionally, machine learning algorithms generate predictive models of cachexia risk, enabling preventative measures. A novel composition of matter featuring a synergistic blend of L-arginine, omega-3 fatty acids, vitamin A, and dietary nucleotides enhances the body's natural immune response. Furthermore, a computer-implemented system analyzes genomic data to identify genetic markers associated with increased cachexia risk, providing personalized nutritional recommendations. Finally, gene editing technology is employed to modify the expression of genes involved in myeloid-derived suppressor cells and pro-inflammatory cytokines, preventing or treating surgery-induced cachexia.

The new claims introduce a paradigm shift in cachexia prevention and treatment by incorporating wearable devices, machine learning, novel compositions of matter, and gene editing technology. These innovations provide a personalized, adaptive, and precision-based approach that surpasses the original patent's standardized supplement-based methods.

Alternative embodiments may include the use of implantable devices, mobile applications, or telemedicine platforms to monitor biomarkers and provide personalized interventions. Variations may also involve the integration of additional biomarkers, genetic markers, or physiological responses to further enhance the predictive models and personalized recommendations.

The new inventive concept has significant commercial potential in the healthcare and nutrition industries, particularly in the areas of personalized medicine, precision nutrition, and gene editing technology. Target markets may include hospitals, clinics, and healthcare providers, as well as consumers seeking personalized nutrition and wellness solutions.